

CITATION REPORT

List of articles citing

Pan-cancer efficacy of pralsetinib in patients with RET fusionpositive solid tumors from the phase 1/2 ARROW trial

DOI: 10.1038/s41591-022-01931-y
, 2022, 28, 1640-1645.

Source: <https://exaly.com/paper-pdf/150265643/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	ARROW: pralsetinib hits target across cancers.		
31	Tissue-agnostic RET inhibition: can you trust your target?. 2022 , 23, 1235-1237		0
30	The Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer. 2022 ,		6
29	Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan. 2022 , 29, 7272-7284		0
28	Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102).		0
27	Targeted RET inhibitor therapy effective in treating multiple cancer types. 2022 , 128, 4040-4040		0
26	Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalized medicine ?. 2022 ,		1
25	Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP). 2022 , 174, 118-124		0
24	Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies. 2022 ,		0
23	Recurrent RET fusions in fibrosarcoma-like neoplasms in adult viscera: expanding the clinicopathological and genetic spectrum.		0
22	Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. 2022 , 14, 6223		1
21	Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. 2022 ,		0
20	Precious Gene: The Application of RET-Altered Inhibitors. 2022 , 27, 8839		0
19	TFG::MET -rearranged soft tissue tumor: A rare infantile neoplasm with a distinct low-grade triphasic morphology.		0
18	RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. 2023 , 108344		1
17	The next generation of evidence-based medicine.		6
16	Molecular Tumor Board at European Institute of Oncology: report of the first three year activity of an Italian precision oncology experience.. 2023 ,		0

- 15 Genomic landscape of 891 RET fusions detected across diverse solid tumor types. **2023**, 7, ○
- 14 Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single center study.. ○
- 13 A comprehensive overview of the relationship between RET gene and tumor occurrence. 13, ○
- 12 Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. **2023**, 15, 664 ○
- 11 Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the NSCLC of GI Oncology?. **2023**, 15, 1578 ○
- 10 RET signaling in breast cancer therapeutic resistance and metastasis. **2023**, 25, ○
- 9 Precision Oncology Targets in Biliary Tract Cancer. **2023**, 15, 2105 ○
- 8 Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma. **2023**, 7, 1
- 7 Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials. **2023**, ○
- 6 Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. ○
- 5 Aktuelle Entwicklungen in der palliativen Therapie biliärer Tumoren. **2023**, 10, 44-48 ○
- 4 RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report. 13, ○
- 3 Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer. **2023**, 23, ○
- 2 Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. **2023**, 16, 614 ○
- 1 Update on Emerging Therapies for Advanced Colorectal Cancer. **2023**, ○